Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Edna N Bosire1, Lucy Wambui Kamau2, Chinedu T Udeh-Momoh2,3
1Brain and Mind Institute, Aga Khan University, Nairobi, Nairobi, Kenya.
Background:
Advancements in dementia research are in part contingent on participation in clinical research. Clinical trials can help researchers determine if new drugs, devices, or diagnostic procedures for dementia are safe and effective. However, little is known about clinical trials for dementia in resource constrained settings such as Kenya. The aim of our research was to explore people's understanding of dementia clinical trials, their attitudes and perceptions towards dementia clinical trials and what can be done to enhance enrollments on such clinical trials.
Method:
This was an ethnographic study involving 8 focused group discussions (FGDs; age and gender stratified; n=81) in Nairobi to understand people's perceptions about dementia clinical trials. All FGDs were conducted in both English and Kiswahili each lasting about 90 minutes and took place in Kibera and Mathare informal settlements in Nairobi, Kenya. Data were transcribed verbatim and thematically analyzed by Nvivo version 14 software.
Result:
Younger participants had a basic understanding of clinical trials compared to older participants. Participant's willingness to engage in clinical trials for dementia research varied across age and gender groups, and this was influenced by both individual and collective perceptions. Many participants expressed their willingness to participate if they believed the research would contribute to a greater good, such as helping others, improving healthcare or contributing to medical advancement. However, there was hesitation, driven by fear of side effects, concerns about the integrity of the research process, and religious or cultural beliefs. For future motivation to participate in dementia clinical trials, participants recommended a need to ensure their families were involved in such studies, provide financial incentives and sensitizing community members on potential benefits of being participants in clinical trials.
Conclusion:
Findings reported from our study may be useful in developing strategies that can enhance participation in dementia clinical research and advance efforts dedicated to finding effective treatments for dementia in Kenya and other similar contexts.
Insights
Understanding dementia clinical trials in Kenya is crucial for advancing research. Enhancing enrollment requires addressing concerns about side effects, research integrity, and cultural beliefs, while highlighting benefits and offering incentives.
Area of Science:
- Neuroscience
- Clinical Research
- Public Health
Background:
- Dementia research relies on clinical trial participation to test new treatments.
- Understanding dementia clinical trials in resource-constrained settings like Kenya is limited.
- This study explores perceptions of dementia clinical trials in Nairobi, Kenya.
Purpose of the Study:
- To explore public understanding of dementia clinical trials.
- To assess attitudes and perceptions towards dementia clinical trials.
- To identify strategies for enhancing enrollment in dementia clinical trials.
Main Methods:
- An ethnographic study utilized 8 focused group discussions (FGDs) with 81 participants in Nairobi.
- FGDs were age and gender stratified, conducted in English and Kiswahili.
- Thematic analysis of transcribed data was performed using NVivo software.
Main Results:
- Younger participants showed better understanding of clinical trials than older ones.
- Willingness to participate varied by age and gender, influenced by perceptions of contributing to a greater good.
- Hesitancy stemmed from fear of side effects, research integrity concerns, and cultural/religious beliefs.
Conclusions:
- Study findings can inform strategies to boost dementia clinical research participation in Kenya.
- Addressing community concerns and highlighting benefits are key to enhancing enrollment.
- This research contributes to advancing dementia treatment efforts in similar global contexts.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation